Syndax Pharmaceuticals price objective cut to $23 from $26 by BofA Global Research
SNDX•BofA Global Research cut its price objective for Syndax Pharmaceuticals to $23 from $26.
Related News
JPMorgan raises price target on Phillips 66 to $275, citing stronger refining margins
PSX•
Agora CEO Zhao Bin reports $441,867 purchase of company shares
API•
JPMorgan Chase posts Q3 2026 financial results report on investor relations website
JPM•
U.S. stocks on the move: Johnson & Johnson, JPMorgan, UnitedHealth, Goldman Sachs
SPY•
Duncan Aviation places prepaid order for 40 Gogo Galileo HDX systems
GOGO•